The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Acquired chemotherapy resistance in ovarian cancer
Open accessAbstract
Most women diagnosed with high-grade serous ovarian cancer (HGSC) develop recurrent disease and chemotherapy resistance, despite initially responding to treatment. The genomic characteristics of HGSC samples collected at initial surgery have been extensively studied. However, due to challenges of sample collection following treatment, much less is known about the molecular features of recurrent disease. Our recent studies have identified mechanisms of acquired resistance and biomarkers in recurrent HGSCs that could lead to improved treatment approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the majority of OvCa patients that initially respond to chemotherapy treatment develop the recurrent disease due to acquired resistance to platinum-based chemotherapy after undergoing multiple cycles of chemotherapy36.”
From Large-scale integrated analysis of ovarian cancer tumors and cell lines identifies an individualized gene expression signature for predicting response to platinum-based chemotherapy (2019) · cites this paper as [36]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“High-grade serous ovarian cancers (HGSOC) are the most prevalent type of epithelial ovarian tumors (about 75%) and characterized by TP53 driver mutations and extensive genome rearrangement (Christie and Bowtell, 2017).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Christie and Bowtell, 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Whole–genome characterization of chemoresistant ovarian cancer
Patch, A., Christie, E. L., Etemadmoghadam, D., Garsed, D. W., George, J., Fereday, S., Nones, K., Cowin, P. A., Alsop, K., Bailey, P. J., et al. (2015) · Nature · doi:10.1038/nature14410 · Cited by 1,572
Self-citationRethinking ovarian cancer: recommendations for improving outcomes
Vaughan, S., Coward, J. I. G., Bast, R. C., Berchuck, A., Berek, J. S., Brenton, J. D., Coukos, G., Crum, C. P., Drapkin, R., Etemadmoghadam, D., et al. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3144 · Cited by 1,484
Self-citationAlsop, K., Fereday, S., Meldrum, C. J., DeFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M. J., Webb, P. M., Stewart, C. J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.8545 · Cited by 1,204
Self-citationDriver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
Ahmed, A. A., Etemadmoghadam, D., Temple, J., Lynch, A. G., Riad, M., Sharma, R. N., Stewart, C. J. R., Fereday, S., Caldas, C., DeFazio, A., et al. (2010) · The Journal of Pathology · doi:10.1002/path.2696 · Cited by 815
Self-citationNorquist, B. M., Wurz, K., Pennil, C. C., Garcia, R. L., Gross, J., Sakai, W., Karlan, B. Y., Taniguchi, T., & Swisher, E. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.2980 · Cited by 593
Evolution of platinum resistance in high-grade serous ovarian cancer
Cooke, S. L., & Brenton, J. D. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70123-1 · Cited by 213
Christie, E. L., Fereday, S., Doig, K., Pattnaik, S., Dawson, S., & Bowtell, D. D. L. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.4627 · Cited by 198
Self-citationDNA-PK Mediates AKT Activation and Apoptosis Inhibition in Clinically Acquired Platinum Resistance
Stronach, E. A., Chen, M. M., Maginn, E. N., Agarwal, R., Mills, G. B., Wasan, H. S., & Gabra, H. (2011) · Neoplasia · doi:10.1593/neo.111032 · Cited by 138
Cited by
Sorted by citations
Items 201–221 of 221
Additional file 13 of The R-enantiomer of ketorolac reduces ovarian cancer tumor burden in vivo
Grimes, M. M., Kenney, S. R., Dominguez, D. R., Brayer, K. J., Guo, Y., Wandinger‐Ness, A., & Hudson, L. G. (2021) · Figshare · doi:10.6084/m9.figshare.13545569
Additional file 5 of The R-enantiomer of ketorolac reduces ovarian cancer tumor burden in vivo
Grimes, M. M., Kenney, S. R., Dominguez, D. R., Brayer, K. J., Guo, Y., Wandinger‐Ness, A., & Hudson, L. G. (2021) · Figshare · doi:10.6084/m9.figshare.13545587
Additional file 8 of The R-enantiomer of ketorolac reduces ovarian cancer tumor burden in vivo
Grimes, M. M., Kenney, S. R., Dominguez, D. R., Brayer, K. J., Guo, Y., Wandinger‐Ness, A., & Hudson, L. G. (2021) · Figshare · doi:10.6084/m9.figshare.13545596
Additional file 2 of The R-enantiomer of ketorolac reduces ovarian cancer tumor burden in vivo
Grimes, M. M., Kenney, S. R., Dominguez, D. R., Brayer, K. J., Guo, Y., Wandinger‐Ness, A., & Hudson, L. G. (2021) · Figshare · doi:10.6084/m9.figshare.13545578
Additional file 4 of The R-enantiomer of ketorolac reduces ovarian cancer tumor burden in vivo
Grimes, M. M., Kenney, S. R., Dominguez, D. R., Brayer, K. J., Guo, Y., Wandinger‐Ness, A., & Hudson, L. G. (2021) · Figshare · doi:10.6084/m9.figshare.13545584
Additional file 6 of The R-enantiomer of ketorolac reduces ovarian cancer tumor burden in vivo
Grimes, M. M., Kenney, S. R., Dominguez, D. R., Brayer, K. J., Guo, Y., Wandinger‐Ness, A., & Hudson, L. G. (2021) · Figshare · doi:10.6084/m9.figshare.13545590
Additional file 11 of The R-enantiomer of ketorolac reduces ovarian cancer tumor burden in vivo
Grimes, M. M., Kenney, S. R., Dominguez, D. R., Brayer, K. J., Guo, Y., Wandinger‐Ness, A., & Hudson, L. G. (2021) · Figshare · doi:10.6084/m9.figshare.13545563
Additional file 3 of The R-enantiomer of ketorolac reduces ovarian cancer tumor burden in vivo
Grimes, M. M., Kenney, S. R., Dominguez, D. R., Brayer, K. J., Guo, Y., Wandinger‐Ness, A., & Hudson, L. G. (2021) · Figshare · doi:10.6084/m9.figshare.13545581
Zhu, X., Shijing, Y. O. U., Du, X., Song, K., Lv, T., Zhao, H., & Yao, Q. (2023) · Figshare · doi:10.6084/m9.figshare.22602632
Additional file 10 of The R-enantiomer of ketorolac reduces ovarian cancer tumor burden in vivo
Grimes, M. M., Kenney, S. R., Dominguez, D. R., Brayer, K. J., Guo, Y., Wandinger‐Ness, A., & Hudson, L. G. (2021) · Figshare · doi:10.6084/m9.figshare.13545560
Targeting circSFPQ_008/SFPQ/BRCA1 axis for overcoming platinum resistance in ovarian cancer
Jiang, Y., Zhou, D., Liu, Y., Li, B., Liu, R., LI, J., & Sheng, X. (2026) · MedScience · doi:10.1007/s11684-026-1201-7
Cisplatin-synergistic monoterpene indole alkaloids with diverse scaffolds from Rauvolfia vomitoria
Yang, K., Liu, Z., Ma, X., Wang, N., Qi, Q., Huang, X., Zhan, G., & Guo, Z. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110120
Zhang, J., Xu, L., Guo, K., Dong, W., Dai, X., & Gu, D. (2026) · Journal of Cell Communication and Signaling · doi:10.1002/ccs3.70085
Zhang, B., Chen, R., Ben, P., Zhang, B., & Li, Y. (2026) · Research Square · doi:10.21203/rs.3.rs-9590591/v1
Li, M., Xu, Y., Mai, Z., Ren, L., Yu, X., Chen, S. S., Ke, Z., & Yu, R. (2026) · CytoJournal · doi:10.25259/cytojournal_99_2025
Diversity within ovarian cancer subtypes and their tumor microenvironment
Winstone, L., Bevelander, B. B., & Chamberlain, M. D. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1876327
Li, Y., Zou, J., Yang, L., Tan, X., Tang, X., Wu, P., Liu, X., Chen, X., Wu, D., & Xing, Y. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-03071-z
Zhou, L., Mingrui, J., Yueyang, Z., Hang, Q., Liu, Q. S., Xiaoyu, Y., Yu, H., & Meihui, X. (2026) · Cancer Reports · doi:10.1002/cnr2.70637
Geng, Z., Wang, Z., Pan, X., Xia, C., Wang, H., Wang, X., Xu, H., Xu, J., & Jia, X. (2026) · Translational Oncology · doi:10.1016/j.tranon.2026.103056
Metadata
- Authors
- Christie, E. L., & Bowtell, D. D. L.
- Affiliations
- The University of Melbourne (AU)
- Corresponding author
- Christie, E.L.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2017-11
- Volume
- 28
- Issue
- suppl_8
- Pages
- viii13-viii15
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2772038399
- Cited by
- 220
- References
- 14
- Citations by year
- 2026: 13 · 2025: 13 · 2024: 31 · 2023: 35 · 2022: 38 · 2021: 47 · 2020: 26 · 2019: 15 · 2018: 2
- FWCI
- 13.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Health and Medical Research Council (APP1092856)
- NHMRC (GNT1124309)
- Victorian Cancer Agency (ECSG15012)
- U.S. Army Medical Research and Materiel Command (DAMD17-01-1-0729)
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- high-grade serous ovarian cancer, recurrent ovarian cancer, biomarkers, drug resistance mechanisms
- MeSH terms
- Antineoplastic Agents, Female, Humans, Neoplasm Recurrence, Local, Ovarian Neoplasms, Cystadenocarcinoma, Serous, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
